Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 8/20 | 0.48 |
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428462 | 0.86 | PKM (0.51) | PKMNPC1RAB9ADRD3DRD2 | |
| SCHEMBL30163480 | 0.86 | POLB (0.47) | PKMNPC1DRD3DRD2KMT2A | |
| SCHEMBL31428943 | 0.79 | SCN9A (0.41) | PKMNPC1RAB9AKMT2AKDM2B | |
| SCHEMBL763421 | 0.78 | KCNA5 (0.70) | PKMDRD3DRD2NAMPTKCNA5 | |
| SCHEMBL23742769 | 0.77 | HRH3 (0.49) | HRH3HPGDTSHR | |
| SCHEMBL30163530 | 0.77 | SCN9A (0.54) | KDM2BTLR9TLR8TLR7HPGD | |
| SCHEMBL31428645 | 0.77 | HPGD (0.57) | PKMKMT2AHRH3HPGDTSHR | |
| SCHEMBL12835048 | 0.76 | LDHA (0.63) | DRD3DRD2NAMPTKCNA5HPGD | |
| SCHEMBL31428637 | 0.76 | HPGD (0.47) | NPC1RAB9AKMT2AKDM2BHPGD | |
| SCHEMBL19145557 | 0.74 | DRD3 (0.61) | DRD3DRD2NAMPTKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | PKM 4478/4885NPC1 3237/4885RAB9A 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.